Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide

Jean Chemin, Arnaud Monteil, Edward Perez-Reyes\textsuperscript{1}, Joël Nargeot and Philippe Lory\textsuperscript{2}

IGH-CNRS UPR, 1142–141 rue de la Cardonille, F-34396 Montpellier cedex 05, France and \textsuperscript{1}Department of Pharmacology, University of Virginia, 1300 Jefferson Park Avenue, Charlottesville, VA 22908, USA

\textsuperscript{2}Corresponding author

e-mail: philippe.lory@igh.cnrs.fr

Low-voltage-activated or T-type Ca\textsuperscript{2+} channels (T-channels) are widely expressed, especially in the central nervous system where they contribute to pacemaker activities and are involved in the pathogenesis of epilepsy. Proper elucidation of their cellular functions has been hampered by the lack of selective pharmacology as well as the absence of generic endogenous regulations. We report here that both cloned (\(\alpha_{T1G}, \alpha_{T1H}\) and \(\alpha_{T1S}\) subunits) and native T-channels are blocked by the endogenous cannabinoid, anandamide. Anandamide, known to exert its physiological effects through cannabinoid receptors, inhibits T-currents independently from the activation of CB1/CB2 receptors, G-proteins, phospholipases and protein kinase pathways. Anandamide appears to be the first endogenous ligand acting directly on T-channels at submicromolar concentrations. Block of anandamide membrane transport by AM404 prevents T-current inhibition, suggesting that anandamide acts intracellularly. Anandamide preferentially binds and stabilizes T-channels in the inactivated state and is responsible for a significant decrease of T-currents associated with neuronal firing activities. Our data demonstrate that anandamide inhibition of T-channels can regulate neuronal excitability and account for CB receptor-independent effects of this signaling molecule.

Keywords: anandamide/cannabinoid receptor/NG 108-15 cells/pharmacology/T-type calcium channel

Introduction

Voltage-dependent Ca\textsuperscript{2+} channels are divided into three families: the L-type channels (or Ca\textsubscript{v}1), the neuronal N-, P/Q- and R-type channels (or Ca\textsubscript{v}2) and the T-type channels (or Ca\textsubscript{v}3) (Ertel et al., 2000). T-type Ca\textsuperscript{2+} channel (T-channel) hallmarks are low-voltage-activated Ca\textsuperscript{2+} currents, fast inactivation and slow deactivation kinetics, low unitary conductance and strong steady-state inactivation at physiological resting potential (Carbone and Lux, 1984; Armstrong and Matteson, 1985; Nilius et al., 1985; Nowacky et al., 1985; Bean and McDonough, 1998). Three genes encoding the T-channel pore subunits were identified recently and designated \(\alpha_{T1G}\) (Ca\textsubscript{v}3.1), \(\alpha_{T1H}\) (Ca\textsubscript{v}3.2) and \(\alpha_{T1}\) (Ca\textsubscript{v}3.3) (Cribbs et al., 1998; Perez-Reyes et al., 1998; Klugbauer et al., 1999; Lee et al., 1999; Monteil et al., 2000a,b). T-currents generated by the \(\alpha_{T1}\) subunit display slow kinetics that differ markedly from the \(\alpha_{T1G}\) and \(\alpha_{T1H}\) currents, which share the typical signature of native T-currents (Lee et al., 1999; Monteil et al., 2000b). Northern blot analyses have shown that the \(\alpha_{T1G}, \alpha_{T1H}\) and \(\alpha_{T1}\) mRNAs are expressed in various tissues, including heart and central nervous system (CNS) (Cribbs et al., 1998; Lee et al., 1999; Monteil et al., 2000a,b). In the CNS, T-channels generate low threshold spikes and participate in spontaneous firing (Llinas and Yarom, 1981; Llinas and Jahnson, 1982; Huguenard, 1996). T-channels are also involved in cardiac pacemaker activity (Hagiwara et al., 1988; Lei et al., 1998), aldosterone secretion (Rossier et al., 1996) and fertilization (Arnoult et al., 1996). Unfortunately, the lack of selective blockers and endogenous ligands targeting T-channels has considerably hampered the elucidation of their functional roles (Huguenard, 1996).

A recent report describing that arachidonic acid (AA) inhibits \(\alpha_{T1H}\) currents (Zhang et al., 2000) suggested to us that anandamide (N-arachidonoyl-ethanolamine) (Devane et al., 1992) was a potential modulator of T-channel function. Anandamide and 2-arachidonyl glycerol (2-AG) are endogenous ligands of the cannabinoid (CB) receptors, which belong to the G-protein-coupled receptor superfamily. To date, two CB receptors have been cloned, the CB1 receptor expressed primarily in the brain (Matsuda et al., 1990) and the CB2 receptor expressed in the immune system (Munro et al., 1993). CB1 receptor activation inhibits adenyl cyclase, increases mitogen-activated protein kinase activities, modulates several potassium channel conductances and inhibits N- and P/Q-type Ca\textsuperscript{2+} channels (Mackie and Hille, 1992; Bouaboula et al., 1995; Mackie et al., 1995; Twitchell et al., 1997; Schweitzer, 2000). Anandamide preferentially binds to the CB1 receptor and mimicks most effects of the major psychoactive component of marijuana, \(\Delta^8\)-tetrahydrocannabinol (\(\Delta^8\)-THC), such as enhancement of sensory perception, alteration in cognition, sedation, catalepsy, analgesia and hypothermia (Di Marzo et al., 1998; Mechoulam et al., 1998; Ameri, 1999). Nevertheless, several physiological roles for anandamide, including modulation of neuronal excitability (Venence et al., 1995; Tognetto et al., 2001), pain (Adams et al., 1998; Vivian et al., 1998) and cardiovascular functions (Lake et al., 1997; Jarai et al., 1999; Zygmun et al., 1999) are independent of the CB1 receptor activation. Indeed, anandamide can directly activate VR-1 vanilloid receptors (Zygmun et al., 1999), inhibit Kv1.2 and TASK-1 potassium channels (Poling et al., 1996; Maingret et al., 2001) or act on as yet unidentified targets. In the present study, we provide clear evidence that submicromolar concentrations of anandamide directly block T-type calcium channels, which
therefore represent a novel molecular target for this endocannabinoid.

Results

Micromolar concentrations of anandamide inhibited the three human cloned T-channels \( \alpha_{1G} \) (CAv3.1), \( \alpha_{1H} \) (CAv3.2) and \( \alpha_{1I} \) (CAv3.3) expressed in HEK 293 cells (Figure 1). The \( \alpha_{1H} \) and \( \alpha_{1I} \) currents were blocked strongly by 1 \( \mu M \) anandamide by \(-65\) and \(-45\%\) \((I/I\) control: \(0.37 \pm 0.02, n = 17\) and \(0.56 \pm 0.04, n = 15\), respectively), while \( \alpha_{1G} \) currents were inhibited by \(20\%\) at this concentration \((I/I\) control: \(0.81 \pm 0.02, n = 12\)). These results were observed at every potential (Figure 1A–C) using either extracellular \(Ca^{2+}\) (2 mM) or \(Ba^{2+}\) (5 mM; \(n = 10\)). This current inhibition was selective to T-channels since no effect was observed on \( \alpha_{1C} \) currents (Figure 1D), even when increasing the anandamide concentration to 10 \( \mu M \) \((n = 5, \text{not shown})\). A similar anandamide inhibition of \( \alpha_{1H} \) currents was observed in HEK 293, COS and CHO cells (Figure 1E), indicating further that the reported effects were not restricted to HEK 293 cells.

The ability of various cannabinoids to inhibit \( \alpha_{1H} \) currents was then investigated (Figure 2A–E). Similarly to anandamide, the non-hydrolysable analogue methanandamide (1 \( \mu M \)) decreased \( \alpha_{1H} \) currents by \(-70\%\) \((I/I\) control: \(0.31 \pm 0.09, n = 10\)), indicating that anandamide hydrolysis was not involved in the described effects (Figure 2A and C). In contrast, neither of the synthetic CB1/CB2 receptor agonists WIN 55,212-2 (WIN, Figure 2B) and CP 55,490 decreased \( \alpha_{1H} \) currents (Figure 2C). Similarly, neither the endocannabinoid 2-AG nor \( \Delta^{2}\)-THC affected \( \alpha_{1H} \) currents (Figure 2C). The CB1/CB2 agonist HU-210 had no significant effect on \( \alpha_{1H} \) currents at 1 \( \mu M \) (Figure 2C), but inhibited 65\% of the current at 10 \( \mu M \) \((I/I\) control: \(0.35 \pm 0.05, n = 7\)). We next tested the ability of the CB1 receptor antagonist SR141716A to prevent inhibition of \( \alpha_{1H} \) currents by anandamide. Although 100 nM SR141716A produced a mild inhibition \((-20\%) \) of \( \alpha_{1H} \) currents by itself \((I/I\) control: \(0.81 \pm 0.04, n = 14\)), it failed to prevent current inhibition by anandamide \((51 \pm 8\%, n = 8\) and methanandamide \((64 \pm 7\%, n = 6\); Figure 2D and E). An important block of \( \alpha_{1H} \) currents was observed using 1 \( \mu M \) SR141716A \((70 \pm 6\%, n = 6\); not shown).
Activation of CB receptors is known to activate Gi/Go proteins and to regulate various phospholipases (i.e. PLA₂, PLC and PLD) and phosphorylation pathways including protein kinases A and C (PKA and PKC). Application through the patch pipette of 1 mM of GDPβS, an inhibitor of G-protein activity, or cell incubation with 50 μM H7, an inhibitor of cyclic nucleotide-dependent protein kinases, did not prevent the inhibition of α₁H currents by anandamide (Figure 2F). Similar results were obtained with cells incubated in the presence of 100 nM phorbol 12-myristate 13-acetate (PMA), which affects PLC/PKC but also PLD pathways in HEK-293 cells (reviewed in Exton, 1999), or in the presence of 250 μM aristolochic acid, an inhibitor of PLA₂ (Figure 2F). More importantly, inhibition of α₁H currents was observed in excised inside-out patches of HEK 293 cells superfused in the presence of 3 μM anandamide (I/II control: 0.15 ± 0.07, n = 6; Figure 2G), suggesting further that anandamide binds directly to T-channels. In addition, experiments in the presence of AM404, which inhibits the membrane transport of anandamide, were performed. Although extracellular application of AM404 (10 μM) produced a mild inhibition (~30%) of α₁H currents by itself (I/II control: 0.69 ± 0.03, n = 5; Figure 2H), it prevented current inhibition by anandamide (I/II control: 0.6 ± 0.03, n = 5), suggesting that anandamide possibly acts at an intracellular site. Overall, these results demonstrate that neither CB receptors, G-protein pathways nor protein kinases and phospholipases are involved in the inhibition of α₁H currents by anandamide and strongly suggest that anandamide directly inhibits T-channels by acting at an intracellular site.

Anandamide block of native T-channels was examined using the neuroblastoma NG108-15 cell line, which expresses well characterized T-channels (Randall and Tsien, 1997) and most of the high-voltage-activated (HVA) channels (Lukyanetz, 1998). Mackie and Hille (1992) demonstrated that in this cell line, activation of CB₁ receptors by WIN leads to a pertussis toxin-dependent block of N-currents without any effect on T-currents. As for cloned T-channels, methanandamide but not WIN decreased native T-currents in the NG108-15 cell line (Figure 3A and B). In contrast, both compounds significantly inhibited HVA currents (Figure 3C–F) by acting on CB₁ receptors (Mackie and Hille, 1992). The percentages of block by 1 μM methanandamide were 65 ± 6% (n = 12) on T-currents and 31 ± 14% (n = 8) on HVA currents (Figure 3E), while those mediated by 1 μM WIN were 5 ± 9% (n = 11) on T-currents and 43 ± 15% (n = 11) on HVA currents (Figure 3F). The extent of block by methanandamide, as well as its time course (not shown) is similar for cloned and native T-channels. Similar results were obtained using 1 μM anandamide (n = 5, not shown).

Inhibition of Ca²⁺ currents generated by the three cloned T-channels was concentration dependent (Figure 4). Using a holding potential (HP) of −80 mV, submicromolar concentration of anandamide as low as 10 nM significantly decreased α₁H and α₁I currents, while concentrations higher than 100 nM were required to inhibit α₁G currents significantly (Figure 4A and C). Dose–response curves indicated IC₅₀ values of 330 ± 66 nM, n = 8 for α₁H, 1.10 ± 0.05 μM, n = 8 for α₁I and 4.15 ± 0.03 μM, n = 8 for α₁G; and Hill slope factors were 0.60 ± 0.05, n = 8 for α₁H, 0.68 ± 0.05, n = 8 for α₁I and 0.98 ± 0.02, n = 8 for α₁G (Figure 4C). The time course of the α₁H current block by increasing concentrations of anandamide was fast and reached steady state in <1 min (Figure 4B). Current inhibition by anandamide was partially reversible. Recovery was ~15% of the total current after 10 min of washout of the drug (n = 5, not shown). Anandamide had little effect on membrane capacitance (7 ± 14%, n = 8, not shown), indicating that its effects could not be explained by simple membrane-disrupting mechanisms.

Closer inspection of T-currents revealed that anandamide also affects their kinetics (Figure 5). Anandamide accelerated inactivation kinetics of the three cloned T-channels in a concentration-dependent way. This effect was most pronounced for α₁I currents (significant at 100 nM; Figure 5A), while faster kinetics for α₁G and α₁H currents were observed at higher concentrations (1 and 10 μM, respectively; Figure 5B and C). Anandamide-induced acceleration of kinetics occurred at all voltages, especially in the negative range of potentials (not shown). Although 1 μM anandamide produced strong effects on inactivation kinetics, it also significantly accelerated the activation kinetics of α₁G and α₁H currents for potentials lower than −10 mV (P <0.01). Activation kinetics were faster by 1.4- (n = 9), 1.1- (n = 6) and 2-fold (n = 8) at −40 mV for α₁G, α₁H and α₁I, respectively (not shown).
It is interesting to note that the $\alpha_{11}$ currents, which display the slowest kinetics, are the most markedly modulated by anandamide. As a consequence, the sustained component of $\alpha_{11}$ current measured 200 ms after the beginning of the test pulse was abolished in the presence of 1 $\mu$M anandamide (Figure 5A). Anandamide-induced acceleration of the inactivation kinetics suggested that it could also modulate steady-state inactivation of T-channels. In order to test this hypothesis, steady-state inactivation protocols were performed in the presence of anandamide concentrations that approximately blocked 50% of T-currents at −80 mV [the half-potential value ($V_{0.5}$) of steady-state inactivation]. Anandamide shifted the steady-state inactivation curves ($h_{\infty}$) of T-channels (Figure 6A and B) towards more negative potentials (−12.2 ± 2.5 mV, n = 8 for $\alpha_{1G}$, −10.2 ± 2.2 mV, n = 8 for $\alpha_{1H}$, and −12.1 ± 2.1 mV, n = 8 for $\alpha_{1I}$). No shift was observed for steady-state activation curves ($m_{\infty}$). Consequently, the window current generated by the overlapping steady-state activation and inactivation curves was decreased markedly (Figure 6A). Such a negative shift of the steady-state inactivation curve would suggest that anandamide binds and stabilizes T-channels in the inactivated state. A direct method to evaluate anandamide’s binding to inactivated T-channels is to measure the current inhibition at various HPs. We therefore examined the inhibition of $\alpha_{11H}$ currents by 1 $\mu$M anandamide for HPs ranging from −110 to −70 mV (Figure 6C). Expectedly, anandamide strongly blocked T-currents by 85 ± 8% (n = 7) at −70 mV, while at −110 mV anandamide modestly reduced $\alpha_{11H}$ currents by 8 ± 3% (n = 7).

In order to appreciate better the physiological impact of anandamide’s block of T-currents, we performed voltage clamp experiments using a thalamo-cortical relay cell firing activity as waveform. The $\alpha_{11}$ currents strongly participate in the Ca$^{2+}$ entry during sustained neuronal activities because of their slow inactivation kinetics (Figure 7). Anandamide decreased the amplitude and accelerated the decay of $\alpha_{11}$ currents in a concentration-dependent manner (Figure 7). Remarkably, 100 nM anandamide completely abolished the $\alpha_{11}$ current remaining after the seventh spike. To quantify these effects, the integral of the current was measured for the various anandamide concentrations (Figure 7, inset). Since 100 nM anandamide blocked ~50% of the Ca$^{2+}$ influx, these data clearly indicated that anandamide blocks T-channels more efficiently during neuronal activities than during conventional square step stimulations (IC$_{50}$ ~1 $\mu$M, Figure 4).

**Discussion**

This study demonstrates that submicromolar concentrations of the endocannabinoid anandamide blocks cloned $\alpha_{11H}$ and $\alpha_{11}$ channels (and to a lesser extent $\alpha_{1G}$ channels)
Anandamide inhibition of T-type Ca$^{2+}$ channels

Secondly, other natural CB1/CB2 agonists, including the endocannabinoid 2-AG and Δ$^9$-THC, also fail to affect T-currents. Finally, the non-hydrolysable analogue methanandamide also inhibits T-currents, demonstrating that anandamide hydrolysis to AA is not involved in the inhibition of T-channels. The reported effects are therefore distinct from the recently described inhibition of α$^{14}$H currents by AA (Zhang et al., 2000). Similarly to cloned channels, native T-channels are blocked potently by anandamide and methanandamide. The NG108-15 cell line, which displays typical T-currents but also N-, P/Q-, R- and L-type currents (Randall and Tsien, 1997; Lukyanetz, 1998), was used previously by Mackie and Hille (1992) to demonstrate that activation of CB1 receptors by WIN leads to the inhibition of N-currents, without affecting T-currents. Using this cell line, we demonstrate that anandamide, but not WIN, is a potent blocker of native T-currents, confirming that this inhibition is independent of CB receptors.

Previous studies have described that other signaling molecules modulate native T-currents. Nociceptin, an endogenous ligand of the opioid receptor ORL$^1$, mediates inhibition of T-currents from dorsal root ganglion neurons independently of G-proteins (Abdulla and Smith, 1997). This effect is prevented by the $\kappa_3$ antagonist, nalbuphine, indicating that nociceptin inhibition of T-currents involves receptor activation. Similarly, the 5-hydroxytryptamine inhibition of T-currents in sensory neurons of Xenopus larvae is mediated by a functional domain of the receptor that is distinct from that which couples to G-proteins (Sun and Dale, 1999). In contrast, modulation of T-channels in adrenal glomerulosa cells by angiotensin II and dopamine D1 receptors occurs through G-protein receptor-coupled pathways (McCarthy et al., 1993; Drolet et al., 1997). Overall, anandamide appears to be one of the first endogenous ligands ever described capable of directly modulating T-channels. The IC$^{50}$ values for T-currents

as well as native T-channels. The block is independent of CB receptors, G-proteins, PLA$_2$, PLC, PLD, cyclic nucleotide-dependent protein kinases and PKC. The block is observed in excised inside-out patch configuration, indicating that inhibition of T-currents by anandamide is probably direct. In addition, block of anandamide membrane transport by AM404 (Beltramo et al., 1997) suggests an intracellular action of anandamide. The pharmacological profile of the endocannabinoid block of T-channels is specific for anandamide and further confirms that this molecule acts directly on the T-channels. First, the classical CB1/CB2 agonists WIN and CP 55,490 are inactive and the CB1 receptor antagonist SR141716A does not prevent inhibition of T-currents by anandamide.
inhibition (330 nM for α11H channels) are equivalent to those obtained for the CB1 receptor activation (Felder et al., 1995), suggesting that T-channels could be one of the principal targets of anandamide. Direct effects of anandamide on ionic channels have already been reported. Indeed, anandamide inhibits Kv1.2 potassium channels independently of CB1 receptor activation with an IC50 of 2.7 μM (Poling et al., 1996), and directly activates vanilloid VR1 receptors at even higher concentrations (Zygmunet et al., 1999; Smart et al., 2000). In addition, it was shown recently that submicromolar concentrations of anandamide directly inhibit the potassium channel TASK-1, which underlies the background current IKs (Maingret et al., 2001). Altogether, besides its classical action on CB receptors, anandamide can act directly on several ionic channels, including T-channels, to produce its powerful pharmacological and physiological effects.

Inhibition of T-currents by anandamide is highly dependent on the inactivation state of the channel. Indeed, the block is negligible for HPs lower than −100 mV and reaches ~85% at ~70 mV, an HP at which T-channels are strongly inactivated. In addition, anandamide induces an approximately −10 mV shift of the steady-state inactivation curves of each cloned T-channel, but not of the activation curves. This results in a net decrease of the window current component of T-channels. Overall, these data strongly indicate that anandamide binds and stabilizes T-channels in the inactivated state. Binding to the inactivated T-channels is an important feature of the anandamide block, since T-channels are strongly inactivated at physiological resting potentials. This property could also contribute to tissue selectivity of the anandamide effects. For example, dihydropyridines that bind preferentially to the inactivated state of L-type Ca2+ channels are useful as anti-hypertensive drugs by acting on smooth muscle while having little effect on the heart (Triggle, 1992). Another interesting feature of the block of T-currents by anandamide is the acceleration of current kinetics. T-currents generated by the α11 subunit inactivate slowly (Lee et al., 1999; Monteil et al., 2000b), leading during long test pulses to a sustained current component that is abolished by anandamide. Acceleration of current decay was observed before the decrease in the current amplitude (not shown), suggesting that anandamide could act as an open channel blocker (Bezprozvanny and Tsien, 1995). In that respect, the appearance of a faster inactivation would be due to an increase in the open to blocked transition, which would also explain apparent faster activation kinetics. A similar state-dependent block was described recently for other T-channel blockers such as the antiepileptic drugs methylphenylsuccinimide and ethosuximide (Gomora and Perez-Reyes, 2001). Speed up of current decay is also observed for α1G and α11H subunits but at higher anandamide concentrations, possibly due to their faster inactivation kinetics, as reported for the mibefradil block of HVA Ca2+ channels (Bezprozvanny and Tsien, 1995).

By stimulating cells overexpressing α1T channels with thalamic firing activities, we demonstrate that anandamide block of T-currents is ~10 times more potent during neuronal firing activity (IC50 ~100 nM for α11H channels). This suggests that anandamide could be an important physiological regulator of T-channels. What could be the physiological relevance of the blockade of T-currents by anandamide? First, the fact that anandamide preferentially binds and stabilizes T-channels in the inactivated state suggests that it could significantly decrease T-currents induced by low-threshold spike (LTS). LTS results from deactivation of T-channels after inhibitory synaptic input, leading to a Ca2+-dependent depolarization, which activates sodium channels (Huguenard, 1996). This phenomenon is well known in the thalamus where T-channels are thought to mediate action potentials and to control the frequency and time course of repetitive firing (McCormick and Huguenard, 1992). In the thalamus, T-channels are involved in slow wave sleep (Steriade et al., 1993) and in the pathogenesis of epilepsy (Tsakiridou et al., 1995). It is important to note that a high level of anandamide was detected in the thalamus (Felder et al., 1996) while CB1 receptors are expressed at low levels (Herkenham et al., 1991). It would be of great interest to test on these neurons whether anandamide could modify their activities via non-CB receptor mechanisms. Inhibition of T-channels could also participate in the antinociceptive effects of anandamide. On one hand, the α11H subunit is highly expressed in dorsal root ganglion neurons (Talley et al., 1999) and neuropsychiatric pain alters T-current properties (Hogan et al., 2000). On the other hand, anandamide-induced antinociception is not fully prevented by the CB1 receptor antagonist SR141716A (Adams et al., 1998; Smith et al., 1998; Vivian et al., 1998). In addition, the antinociceptive response attributed to tonic activation of CB1 receptors (Chapman, 1999) could be related to the SR141716A block of T-currents described here. Another important property of the anandamide block is the abolition of the window current component of T-channels. The window current occurs near the resting potential of many excitatory cells. It contributes to the control of basal levels of Ca2+ (Chemin et al., 2000) and potentially participates in cell proliferation and differentiation processes (Bijlenga et al., 2000). The window current is also suspected to participate in the control of the cardiac pacemaker activity (Lei et al., 1998). In the heart, high levels of anandamide but few CB receptors were detected (Felder et al., 1996; Herkenham et al., 1991). It will therefore be important to determine whether direct inhibition of pacemaker T-channels by anandamide or SR141716A also participates in the bradycardic effect of these compounds (Lake et al., 1997). Altogether, anandamide inhibition of T-channels represents a novel non-CB receptor mechanism that can contribute to a wide variety of anandamide’s effects. This strong regulation of T-channels should therefore be taken into account in further studies investigating the physiological roles of anandamide.

Materials and methods

Cell culture and transfection protocols

HEK-293, COS-7, CHO and NG 108-15 cells were cultured using standard techniques. Transfection was performed as previously described (Chemin et al., 2001) with a DNA mix containing 10% of a GFP plasmid and 90% of either of the pBK-CMV plasmid constructs that code for human α1G, α1H, and α11T channel isoforms (Crbbs et al., 1998; Monteil et al., 2000b) or a 1:1:1 ratio of α11G, β3, and γδ1b subunits (Tomlinson et al., 1993). When indicated, 50 μM of the kinase inhibitor 1-(5-isouquinolinesulfonyl)-2-methyl-piperazine (H7, Sigma), 100 nM
PMA (Sigma) or 250 μM aristolochic acid (Sigma) were added in the culture medium 16 h prior to the electrophysiological recordings. For NG 108-15 experiments, cells between 10 and 17 passages were plated at low confluence (~0%) and differentiation was induced 5–10 days before recordings by decreasing the serum content in the medium to 1% and by adding 1 mM cAMP (Sigma).

Electrophysiology

Whole-cell currents were recorded at room temperature as previously described (Chemin et al., 2001). Extracellular solution contained (in mM): 2 CaCl2, 160 TEACl and 10 HEPES (pH to 7.4 with TEA-OH). Pipettes have a resistance of 1–3 MΩ when filled with a solution containing (in mM): 110 CsCl, 10 EGTA, 10 HEPES, 3 Mg-ATP and 0.6 GTP (pH to 7.2 with CsOH). When indicated, 0.6 mM GTP was substituted with 1 mM GDPβS (Sigma). For inside-out patch experiments, a sylgard-coated pipette has a resistance of 8–13 MΩ when filled with a solution containing (in mM): 100 BaCl2, 10 HEPES (pH to 7.2 with TEA-OH). Membrane potential was reduced towards 0 nV by bathing the cells in solution containing (in mM): 140 K gluconate, 10 EGTA, 10 glucose, 1 MgCl2, 10 HEPES (pH to 7.3 with KOH). The sampling frequency for acquisition was 10 kHz and data were filtered at 2 kHz. For action potential clamp studies, a thalamo-cortical relay cell firing activity generated by the NEURON model (Hines and Carnevale, 1997) was used in the configuration of a three-compartment model of burst behaviour (Destexhe et al., 1998) available at Yale University database (http://senselab.med.yale.edu/senselab/neuron). With this model, a firing activity produced by a 0.3 nA current injection in the soma during 700 ms was converted into a pCLAMP stimulation file. In this case, leak and capacitive currents were subtracted using a P/5 procedure. Electrophysiological analysis was performed as previously described (Chemin et al., 2000). Student’s t-tests were used to compare the different values, and were considered significant at P < 0.05. Results are presented as the mean ± SEM, and n is the number of cells used.

Pharmacological agents

Anandamide solution (10 mg/ml) and its vehicle were obtained from Tocris, WIN 55,212-2, CP 55,490 and HU-210 (Tocris) were dissolved at 50 mM in dimethylsulfoxide (DMSO) and AM404 (Tocris) was dissolved at 50 mM in ethanol. 2-A, R+(−)-methanandamide (RBI) and Δ4-THC (Sigma) were dissolved at 20 mM in ethanol. SR141716A (10 mM in DMSO) was a gift from Sanofi Recherche (Montpellier, France). Dilutions were prepared daily from these stocks. Solvents were included in all control solutions. Drugs were applied to cells by a gravity-driven home-made perfusion device, controlled by solenoid valves.

Acknowledgements

We are grateful to E.Bourinet for help with excised patch clamp recordings and stimulating discussions, O.Manzoni, D.Robbe, M.Mangoni, F.Rassendren and S.Dubel for helpful discussions and comments on the manuscript, C.Barrère, S.Chaumont and C.Altier for technical support, and T.P.Sutch for providing α1C, β3, and γ2/δ1b cDNAs. We are also grateful to Sanofi Recherche (Montpellier, France) for the gift of SR141716A. This work was supported in part by the CNRS, the Association pour la Recherche contre le Cancer (ARC) and Association Française contre les myopathies (AFM).

References


Jara,J. et al. (1999) Cannabinoid-induced mesenteric vasodilation
through an endothelial site distinct from CB1 or CB2 receptors. *Proc. Natl Acad. Sci. USA*, **96**, 14136–14141.


Received July 17, 2001; revised October 18, 2001; accepted October 23, 2001